Relmada Therapeutics (RLMD) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 54.2% versus a gain of 0.8%. Over five years, RLMD leads with a -87.0% price change compared with -97.0% for SABS. Relmada Therapeutics is the larger company by market cap ($330.7 million vs $230.2 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RLMD | SABS |
|---|---|---|
| Share price | $3.10 | $2.53 |
| Market cap | $330.68M | $230.20M |
| 1-day change | -3.13% | -2.32% |
| YTD return | -35.82% | -32.35% |
| 1-year return | +54.23% | +0.80% |
| 5-year return | -86.99% | -97.00% |
| EPS (TTM) | $-0.91 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-57.39M | $13.27M |
| 52-week high | $8.00 | $5.15 |
| 52-week low | $1.97 | $2.45 |
| Distance from 52-week high | -61.25% | -50.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +246.77% | +360.08% |
| Average volume | 1.30M | 527.29K |
| Shares outstanding | 106.67M | 90.99M |
| Employees | 17 | 86 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed SABS by 53.4 percentage points over the past year.
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Healthcare · Biotechnology · 17 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Healthcare · Biotechnology · 86 employees
RLMD vs SABS FAQ
Which is bigger, Relmada Therapeutics or SAB Biotherapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $330.68M compared with $230.20M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, RLMD or SABS?
RLMD returned +54.23% over the past 12 months, compared with +0.80% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are Relmada Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.